Hand eczema (HE) is a common skin disease that impairs health-related quality of life (HRQOL). Impairments in HRQOL have already been reported in Japanese HE patients using the Skindex-16. Recently, an instrument to measure disease-specific HRQOL in HE patients was developed by an international expert group, consisting of domains for: (i) symptoms; (ii) emotions; (iii) functioning; and (iv) treatment and prevention. The objective of this study is to translate the English-language version of the Quality of Life Hand Eczema Questionnaire (QOLHEQ) to Japanese and then to validate the Japanese version. The Japanese version of the QOLHEQ, the Dermatological Life Quality Index (DLQI) and a questionnaire regarding basic demographic information, including patient ratings of HE severity, were distributed to Japanese HE patients. Additionally, a dermatologist evaluated patients' HE severity using the Physician Global Assessment. A total of 124 patients with a mean age of 43.7 years were included in the analysis, and 78% of the sample was female. Cronbach's alphas for the domains symptoms, emotions, functioning, and treatment and prevention were 0.76, 0.89, 0.88 and 0.81, respectively. The total QOLHEQ score showed a strong correlation with the DLQI, a moderate correlation with patient-rated severity and weak correlations with dermatologist-rated severity and the number of consultations. The Japanese version of the QOL-HEQ showed excellent reliability and high validity. The Japanese version of the QOLHEQ is ready for use in epidemiological studies to evaluate HRQOL impairments in HE patients.
INTRODUCTION
Hand eczema (HE) is a common disease that is frequently seen in dermatological practise. Although numerous studies have been conducted to determine its prevalence and risk factors, very few studies are available on Japanese patients. Thyssen et al. 1 performed a published work review of epidemiological studies in the general population and reported that the 1-year and lifetime prevalence of HE were approximately 10% and 15%, respectively. HE is often work-related, with a high prevalence especially in occupations involving wet work, such as nursing, medical and service work. 1 In Japan, three population-based studies have been performed. [2] [3] [4] The 1-year prevalence of HE in those Japanese studies, which were performed in an occupational setting, was reported to be much higher than the estimated prevalence of 10% found in the general population. 1 The rates in the Japanese occupational setting were 35% in 305 nurses at a teaching hospital, 2 53.3% in 860 clinical nurses 3 and 36.2% in 528 dental workers. 4 Arase et al. 5 reported that among 176 Japanese HE patients, 44% had work-related HE and lower health-related quality of life (HRQOL) was identified among the sample as assessed using the Skindex-16, which is a skin disease-specific HRQOL tool available in the Japanese language. In addition to the Skindex-16, 6 a Japanese version of the Dermatology Life Quality Index (DLQI) is also available; 7, 8 however, the psychometric properties of the DLQI have been found to be questionable when used in HE populations. 9 Both instruments used in Japan are dermatology-specific and are not designed to assess the specific impairments suffered by HE patients. Recently, an instrument to measure disease-specific HRQOL in HE patients, called the Quality of Life in Hand Eczema Questionnaires (QOLHEQ), was developed by an international expert group, assessing the domains of: (i) symptoms; (ii) emotions; (iii) functioning; and (iv) treatment and prevention. Subsequently, the German version of the QOLHEQ was validated and a cross-cultural validation involving six language versions was carried out. 10, 11 The German-language version of the QOLHEQ was validated using a longitudinal study design with three assessments which were performed in order to determine test-retest reliability and responsiveness. The QOLHEQ was found to have strong measurement properties in terms of validity, reliability and responsiveness to changes. 10 The aim of the present study is to translate the English-language version of the QOLHEQ into Japanese and to validate the new Japanese version with a cross-sectional design to enable its application in Japanese HE patients. In future, the different language versions of the QOL-HEQ can be used to compare HRQOL impairments in HE patients between countries. This enables also the opportunity to perform clinical trials in HE patients across countries and thereby assess HRQOL data in a comparable manner.
METHODS

Translation process
The English-language version of the QOLHEQ was translated into Japanese according to the guidelines published by Ohrbach et al. 12 Bilingual translators who are native Japanese speakers, including one translator with a medical/clinical background and one translator who is a layperson, produced the two independent translations. Each translator produced a written report regarding difficulties encountered. Then, all differences between the two translations were summarized and the two translators worked together with a recording observer (K. M.), who also participated in developing the original QOLHEQ, to reach a consensus regarding the final translated version.
Questionnaire distribution
The QOLHEQ, DLQI and a questionnaire regarding basic demographic information, including the frequency of HE recurrence or persistence, the number of consultations in the last year and the year of diagnosis, were distributed to HE patients. We also assessed patient-rated HE severity; the patients rated the severity of their HE using a numerical rating scale ranging 0-10. Additionally, a dermatologist evaluated each patient's HE severity using the Physician Global Assessment (PGA), a measure of disease severity according to a photographic guide scored on a 5-point Likert scale: 0, "clear"; 1, "almost clear"; 2, "mild"; 3, "moderate"; and 4, "severe". 13 The DLQI is a skin-specific HRQOL measurement instrument with 10 items scored on a 4-point Likert scale. 7 According to its developers, the DLQI can also be used to analyze impairments in HRQOL according to six subdomains: (i) symptom and feelings; (ii) daily activities; (iii) leisure time; (iv) work and school; (v) personal relationships; and (vi) treatment. The patients were recruited by seven dermatologists in clinics or hospitals located in Kumamoto, Japan.
Scoring
The total QOLHEQ score was calculated according to the code published in the German validation study, 10 which is available for download in SPSS or SAS syntax on the website of the developers (www.qolheq.dermis.net). The details of the scoring structure for each item of the QOLHEQ are shown in Table 1 . If only one item in each domain was missing, then the item was scored 0. If two or more items in each domain were missing, then the total domain score of the subject was considered a missing value. Additionally, we also calculated the Raschadjusted values, which were derived from the cross-cultural validation study of the QOLHEQ 11 for each QOLHEQ subscale.
These values are reported separately for males and females in the Supplemental Information of this article and can be used for international comparisons of HRQOL impairment in HE patients.
Analysis
We calculated Cronbach's alpha to assess the internal consistency of each domain of the QOLHEQ. To determine the construct validity, we tested the following hypotheses: the QOLHEQ has a significant and (i) strong correlation with the DLQI, (ii) moderate correlation with patient-rated disease severity, (iii) weak correlation with dermatologist-rated disease severity (PGA) and (iv) weak correlation with the number of dermatologist consultations in the last year, but it is (v) not correlated with the time since HE onset as shown earlier. 10 We also assessed the extent to which each domain of the QOLHEQ is correlated to the reference values. Additionally, we assessed correlations between the QOLHEQ domains and the DLQI domains under the hypotheses that corresponding domains should be strongly correlated, while non-corresponding domains should only show moderate effect sizes. We considered P < 0.05 significant and defined a strong correlation (+++) as r > 0.7, a moderate correlation (++) as 0.7 > r > 0.4 and a weak correlation (+) as 0.4 > r > 0.2.
Ethical issues
All procedures of the present study were approved by the ethics committee of the Faculty of Life Sciences, Graduate School of Kumamoto University.
RESULTS
Translation process
After the translation process was completed as described in the Methods section, the recoding observer discussed the final details regarding the meaning of the questions with the main developer (R. O.) if difficulties were found during translation. Finally, she shared all discussed content with the two translators and a final translation was agreed upon. For four items of the domain emotions (makes me feel "frustrated", "nervous", "annoyed" or "irritated"), some effort was required to determine the appropriate Japanese wording because the translations for the words describing emotional conditions are very similar to each other in Japanese. In addition, the phrase "certain things" in the item "because I have to avoid contact with certain things" was described in more detail ("things that exacerbate skin conditions") in the Japanese translation to ensure easy understanding. The final Japanese translation of the QOLHEQ was pilottested in five patients suffering from HE. The patients completed the Japanese QOLHEQ and then a qualitative interview was conducted regarding difficulties in understanding the items and the answering scale of the QOLHEQ. None of the patients reported experiencing difficulty in understanding or answering the questions of the Japanese QOLHEQ.
Study population
A total of 124 patients with HE were submitted to the analysis. More than half of the subjects were recruited in ordinary dermatological outpatient clinics, and the rest was recruited at the dermatological outpatient division of a private hospital with a capacity of 50 inpatient wards. The mean age was 43.7 years (standard deviation [SD] = 13.9) and 78% of the sample was female. Overall, 70% of the patients reported that their symptoms had lasted for longer than 3 months or recurred at least twice or more in the past year, which is an indicator of chronic HE according to international guidelines. 14 The mean patientrated severity was 5.2 (SD = 2.4). Dermatologist-rated severity evaluated by the PGA was approximately normally distributed with a mean of 2.0 (SD = 0.8). In four patients, the PGA score was 0, but the severity reported by the corresponding patients was not 0. Total QOLHEQ scores were calculated for all 124 subjects; only four subjects had one missing value each. Significant differences were found between males (M) and females (F) in the total QOLHEQ score (M = 42.6 vs F = 57.2, P < 0.01) and patient-rated severity score (M = 4.5 vs F = 5.4, P < 0.05) ( Table 2 ). For the DLQI, only a borderline significant difference between sexes was found (M = 4.8 vs F = 7.1, P = 0.07). The total QOLHEQ score showed a weak correlation with age, with higher scores among younger subjects (r = À0.23, P = 0.011). However, no significant correlation between the dermatologistrated severity score and age was found. Reliability and validity of the QOLHEQ Cronbach's alphas for the domains symptoms, emotions, functioning, and treatment and prevention were 0.76, 0.89, 0.88 and 0.81, respectively. As expected, the total QOLHEQ score showed a strong correlation with the DLQI (r = 0.71, P < 0.001), a moderate correlation with patient-rated severity (r = 0.69, P < 0.001) and weak correlations with the PGA (r = 0.33, P < 0.001) and the number of consultations (r = 0.302, P < 0.01), but no correlation with the time from HE onset. Data regarding hypothesis testing is shown in Table 3 ; the hypotheses on expected correlations of the QOLHEQ with the five reference values were all confirmed. Table 4 shows the correlations of each domain of the QOL-HEQ with total score and the domains of the DLQI. The emotions domain was strongly correlated with the total DLQI score (r = 0.72, P < 0.001), while the other domains showed only moderate correlations. The symptoms and emotions subscales of the QOLHEQ showed strong correlations with the DLQI domain, symptoms and feelings, as expected (r = 0.72, P < 0.001 and r = 73, P < 0.001). The QOLHEQ domain emotions was the only domain correlated with the DLQI domain, personal relationships (r = 0.24, P < 0.05). Only the treatment and prevention subscale among the four QOLHEQ showed a weak correlation with the time from HE onset (r = 0.20, P < 0.05), but no significant correlation with the QOLHEQ total score was found.
DISCUSSION
This is the first validation study of the Japanese-language version of the QOLHEQ. The Japanese version of the QOLHEQ showed excellent internal consistency, had considerably high validity and is now ready for use to evaluate disease-specific HRQOL in HE patients. Each domain of the QOLHEQ showed reasonable results for the strength of correlations with the DLQI domains and the other four reference measures used.
Among Japanese patients, significant differences were found between females and males, with higher scores among female patients for the QOLHEQ and patient-rated severity, but only a borderline significant difference was found for the DLQI and no significant difference was found for dermatologist-rated severity. These results are consistent with the findings of the original QOLHEQ validation study. In general, females show greater impairment in HRQOL compared with males. 15 Our results indicate that the DLQI may not be as sensitive in assessing differences in HRQOL as the QOLHEQ. A Korean study with 138 HE patients also showed only a borderline significant difference between females and males for the DLQI (6.5 for males vs 8 for females, P = 0.062). 16 In addition, a multicenter study of 416 HE patients from 10 European countries showed no significant difference between sexes for the DLQI but a significant difference in the Hand Eczema Severity Index (HECSI), with higher scores among males. 17 In another study directly comparing the generic HRQOL instrument, the 36-Item 
